New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
18:33 EDTISIS, SNYSanofi, Isis announced FDA approval of Kynamro injection
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that the U.S. Food and Drug Administration has approved its New Drug Application for Kynamrotm injection. Kynamro, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol in patients with homozygous familial hypercholesterolemia. Kynamro contains a Boxed Warning citing the risk of hepatic toxicity. Patients taking Kynamro should have liver enzyme testing before starting the drug and periodically thereafter. The safety and effectiveness of Kynamro have not been established in patients with hypercholesterolemia who do not have HoFH. The effect of Kynamro on cardiovascular morbidity and mortality has not been determined.
News For SNY;ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
05:22 EDTSNYGenzyme Cerdelga granted marketing authorization by EC
Subscribe for More Information
January 21, 2015
10:16 EDTSNYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 15, 2015
05:26 EDTISISIsis receives orphan status for myotonic dystrophy drug treatment
Subscribe for More Information
January 14, 2015
07:05 EDTISISIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 12, 2015
08:37 EDTSNYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use